PGEN Earnings Date: Nov 4, 2026 (Estimated) — Precigen, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PGEN's next earnings date?
Precigen, Inc. (PGEN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.06 on revenue of $71.6M.
How did PGEN do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Precigen, Inc. posted EPS of $0.05 versus the -$0.01 estimate, a beat of 600.0%. Revenue was $55.0M against a $27.8M estimate. The stock's 1-day post-earnings move was +5.5%.
How much does PGEN stock move after earnings?
PGEN beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.5% (up or down) in the day after earnings.
About Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.01 | 0.05 | +600.00% | $55.0M | ✅ Beat | +5.51% | +5.05% | +7.35% |
| 2026-05-13 | Q1 2026 | -0.04 | -0.02 | +50.00% | $23.3M | ✅ Beat | +10.84% | +2.89% | +7.23% |
| 2026-03-25 | Q4 2025 | -0.09 | -0.01 | +88.89% | $4.6M | ✅ Beat | +25.48% | +26.77% | +33.23% |
| 2025-11-13 | Q3 2025 | -0.09 | -1.06 | -1077.78% | $2.9M | ❌ Miss | +25.65% | +1.04% | -1.30% |
| 2025-08-12 | Q2 2025 | -0.09 | -0.09 | +0.00% | $856,000 | ➖ Inline | +6.11% | +78.89% | +130.00% |
| 2025-05-14 | Q1 2025 | -0.08 | -0.18 | -125.00% | $1.3M | ❌ Miss | +2.34% | +3.13% | +18.75% |
| 2025-03-19 | Q4 2024 | -0.06 | -0.06 | +0.00% | $1.2M | ➖ Inline | +0.56% | -10.06% | -22.35% |
| 2024-11-14 | Q3 2024 | -0.08 | -0.09 | -12.50% | $953,000 | ❌ Miss | -7.11% | +2.27% | -23.71% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $55.0M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 96.9% | $53.3M | — | — | — | — | — |
| Service | 3.1% | $1.7M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.